VALBIOTIS
7.6.2021 17:42:05 CEST | Business Wire | Press release
Press release
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the appointment of Sébastien BESSY as Chief Operating Marketing and Business Officer.
As of June 8, 2021, Sébastien BESSY will be responsible for the global deployment and coordination of the international strategy related to Valbiotis’ marketing and commercial development in order to support the growth of the Company, and strengthen and develop strategic alliances.
Furthermore, Sébastien BESSY, as a member of the Strategic Direction Board and then of the Supervisory Board of Valbiotis since 2014, will become a member of the Board of Directors as of his appointment.
Sébastien PELTIER, CEO, Chairman of the Board of Directors, comments: "We are delighted to welcome Sébastien BESSY to the Valbiotis Board of Directors. He will drive the Company's ambition at a pivotal time as we prepare the market launch of our first four active substances in development. Sébastien BESSY has in-depth knowledge of the challenges of the healthcare sector with over 20 years of experience in Consumer Healthcare at international pharmaceutical groups. His highly strategic expertise in key markets is a crucial asset that will enable Valbiotis to accelerate its momentum in the future and to strengthen and develop alliances. With our multitarget active substances, we aim to transform the health experiences of millions of people around the world. The appointment of Sébastien BESSY is perfectly in tune with this objective, and the ability to establish our products thanks to high level market expertise will be a decisive asset in shaping Valbiotis' success."
Sébastien BESSY is an expert in the Consumer Healthcare sector, having held various marketing and innovation positions at major pharmaceutical companies over the past 20 years. He has unique international experience, both operational and strategic, in consumer marketing and product innovation, particularly in Europe, Asia including China, North America and Latin America.
During his last 6 years at Ipsen, Sébastien BESSY held the positions of Vice-President Global Marketing & Portfolio Strategy Consumer Healthcare and Vice-President Global Strategic Operations Consumer Healthcare. Prior to joining Ipsen, Sébastien BESSY previously held the positions of Managing Director Europe at Biofortis, a subsidiary of Mérieux Nutrisciences, Global Director of "Probiotic Platform" Innovation at Merck Consumer Healthcare, Global Strategic Marketing Director at Merck Consumer Healthcare and Global Marketing Manager at Reckitt Benckiser.
Sébastien BESSY is a graduate of ISC Paris and began his career at Sanofi Aventis.
Sébastien BESSY adds: ‘I am delighted to join Valbiotis at this time of accelerated development. Throughout my career, in different markets around the world, I have been committed to bringing more and more innovations to patients. I am very excited to join this dynamic company with a clear mission and commitment to develop a new class of plant-based health nutrition products that address unmet needs in the prevention and control of metabolic diseases. Worldwide, 39% of adults are overweight or obese1 , a major risk factor for premature death2 , often associated with metabolic disorders such as elevated fasting blood glucose, dyslipidemia or high blood pressure3 . Hundreds of millions of people around the world are affected. Valbiotis' pipeline and R&D platform represent a source of value for future alliances and a potential for rapid expansion, which will need to be supported by a commercial organization capable of targeting these significant markets, key to our priorities. As a member of the Strategic Direction Board and then of the Supervisory Board of Valbiotis since its creation, I have been able to follow the progress made in just a few years and to appreciate the strength of the strategy implemented, to which I intend to devote all my energy.’
About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com
.
1
World Health Organization, Global Health Observatory, www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-overweight-among-adults-bmi-greaterequal-25-(crude-estimate)-(-)
(consulted on May 27, 2021).
2
World Health Organization, www.emro.who.int/fr/noncommunicable-diseases/causes/unhealthy-diets.html
(consulted on May 27, 2021).
3
The IDF consensus worldwide definition of the metabolic syndrome, International Diabetes Federation, 2006.
Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the Valbiotis registration document, approved by the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com
).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, Valbiotis' shares or securities in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005510/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 02:30:00 CET | Press release
Inaugural event features leaders from Tata Consumer Products and Sun Pharma, highlighting India's growing role in global supply chain innovation Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 22:30:00 CET | Press release
European Commission approval based on data from Phase 3 STOP-HS1 and STOP-HS2, which showed that Povofortay® (povorcitinib) met the primary endpoint at Week 12 and delivered clinically meaningful, durable responses through Week 54 and was well tolerated 1,2 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on res
Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 22:00:00 CET | Press release
Bhatt to lead enterprise technology strategy, AI deployment, and cyber and information security in Executive Leadership Team role Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise work
Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 22:00:00 CET | Press release
Radiation-resilient Lattice Nexus FPGAs have operated as specified in TESAT optical communication terminals since 2025 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platf
New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release
New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
